OBJECTIVE: To describe the frequency of remission in an early rheumatoid arthritis (ERA) cohort. METHODS: The frequency of remission was evaluated, based on 8 definitions including the Boolean-based American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria. RESULTS: Of 369 patients, remission at 12 months ranged from 18% according to the ACR/EULAR clinical trial criteria to 40% according to the 28-joint Disease Activity Score (DAS28) < 2.6. Higher tender joint count, swollen joint count, and physician global scores were seen for DAS28-based definitions, and patient global assessment (PtGA) scores were almost 5-fold higher for DAS28 remission. CONCLUSION: Remission is achievable in ERA but its frequency differs according to the remission definition applied. Adoption of the new ACR/EULAR definition will limit the number classified as in remission, especially if the PtGA criteria are rated high for reasons other than inflammatory arthritis.
OBJECTIVE: To describe the frequency of remission in an early rheumatoid arthritis (ERA) cohort. METHODS: The frequency of remission was evaluated, based on 8 definitions including the Boolean-based American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria. RESULTS: Of 369 patients, remission at 12 months ranged from 18% according to the ACR/EULAR clinical trial criteria to 40% according to the 28-joint Disease Activity Score (DAS28) < 2.6. Higher tender joint count, swollen joint count, and physician global scores were seen for DAS28-based definitions, and patient global assessment (PtGA) scores were almost 5-fold higher for DAS28 remission. CONCLUSION: Remission is achievable in ERA but its frequency differs according to the remission definition applied. Adoption of the new ACR/EULAR definition will limit the number classified as in remission, especially if the PtGA criteria are rated high for reasons other than inflammatory arthritis.
Authors: Josef S Smolen; Jürgen Wollenhaupt; Juan J Gomez-Reino; Walter Grassi; Corine Gaillez; Coralie Poncet; Manuela Le Bars; Rene Westhovens Journal: Arthritis Res Ther Date: 2015-06-11 Impact factor: 5.156
Authors: Peter C Taylor; Rieke Alten; Juan J Gomez-Reino; Roberto Caporali; Philippe Bertin; Emma Sullivan; Robert Wood; James Piercy; Radu Vasilescu; Dean Spurden; Jose Alvir; Miriam Tarallo Journal: RMD Open Date: 2018-03-17
Authors: Kenneth F Baker; Andrew J Skelton; Dennis W Lendrem; Adam Scadeng; Ben Thompson; Arthur G Pratt; John D Isaacs Journal: J Autoimmun Date: 2019-07-04 Impact factor: 14.511
Authors: Michael J Cook; Janet Diffin; Carlo A Scirè; Mark Lunt; Alex J MacGregor; Deborah P M Symmons; Suzanne M M Verstappen Journal: Rheumatology (Oxford) Date: 2016-05-24 Impact factor: 7.580